Clinical and [123I]FP-CIT SPET imaging follow-up in patients with drug-induced parkinsonism

被引:0
作者
Michele Tinazzi
Angelo Antonini
Tommaso Bovi
Isabella Pasquin
Maria Steinmayr
Giuseppe Moretto
Antonio Fiaschi
Sarah Ottaviani
机构
[1] Università di Verona,Dipartimento di Scienze Neurologiche e della Visione
[2] Unita’ Operativa Neurologia OC Borgo Trento,undefined
[3] Parkinson Institute,undefined
[4] Istituti Clinici di Perfezionamento,undefined
[5] Unità Operativa di Medicina Nucleare OC Borgo Trento,undefined
[6] Unita’ Operativa di Psichiatria OC Borgo Trento,undefined
来源
Journal of Neurology | 2009年 / 256卷
关键词
[; I]FP-CIT SPET; Parkinson’s disease; Drug-induced parkinsonism (DIP); Dopamine transporter (DAT);
D O I
暂无
中图分类号
学科分类号
摘要
We recently found that patients with drug-induced parkinsonism (DIP) may have normal (group I) or abnormal (group II) putamen [123I]FP-CIT DAT (dopamine transporter) binding. In this study we reassessed clinical features and DAT binding in 19 of the original 32 patients (10 of group I and 9 of group II) after a 19–39-month follow-up period and tested the effects of chronic levodopa treatment in both cohorts of patients. In group I patients, [123I]FP-CIT SPET (single photon emission tomography) was still normal in all patients at follow-up; DAT binding and UPDRS (Unified Parkinson’s Disease Rating Scale) motor score values did not differ from baseline. In group II patients, [123I]FP-CIT SPET was still abnormal at follow-up; putamen DAT binding was significantly reduced and UPDRS III score higher compared to baseline. Levodopa treatment improved motor symptoms in three out of ten patients of group I and in eight out of nine patients of group II. No adverse psychiatric effects were observed in any of the patients. This study shows that DAT binding imaging may help to identify subjects with DIP secondary to a loss of dopamine nerve terminals in the context of a progressive degenerative parkinsonism. Patients with DIP may benefit from levodopa therapy, particularly when dopamine nerve terminal defects are present, and this should be considered in the therapeutic management of these patients.
引用
收藏
页码:910 / 915
页数:5
相关论文
共 104 条
  • [51] Miller LG(undefined)undefined undefined undefined undefined-undefined
  • [52] Jankovic J(undefined)undefined undefined undefined undefined-undefined
  • [53] Morrish PK(undefined)undefined undefined undefined undefined-undefined
  • [54] Sawle GV(undefined)undefined undefined undefined undefined-undefined
  • [55] Brooks DJ(undefined)undefined undefined undefined undefined-undefined
  • [56] Ottaviani S(undefined)undefined undefined undefined undefined-undefined
  • [57] Tinazzi M(undefined)undefined undefined undefined undefined-undefined
  • [58] Pasquin I(undefined)undefined undefined undefined undefined-undefined
  • [59] Nothdurfter W(undefined)undefined undefined undefined undefined-undefined
  • [60] Tomelleri G(undefined)undefined undefined undefined undefined-undefined